Drug Profile
XEN 2174
Alternative Names: XEN-2174Latest Information Update: 08 Sep 2015
Price :
$50
*
At a glance
- Originator Xenome
- Class Analgesics; Peptides
- Mechanism of Action Adrenergic uptake inhibitors; Catecholamine plasma membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer pain; Postoperative pain
Most Recent Events
- 04 Sep 2012 XEN 2174 is still in phase I/II development for Cancer pain
- 04 Sep 2012 Discontinued - Phase-I for Postoperative pain (in volunteers) in Australia (IV)
- 01 Aug 2012 Xenome completes a phase II trial in Postoperative pain in Bulgaria (EudraCT2010-019109-40)